Name sample on phylogenetic tree (fig. 2)

Complete sample name

Subtype in REGA v.3.0 Subtype in phylogenetic analysis

1

4352

A1 A1

2

6397

G G

3

1128

A1 A1

4

3879

A1 A3

5

6436

A1 A1

6

4238

A1 A1

7

3169

A1 CRF 02AG

8

1786

CRF 02AG CRF 02AG

9

4886

CRF 02AG CRF 02AG

10

2434

CRF 02AG CRF 02AG

11

1912

CRF 02AG CRF 02AG

12

5721

Recombinant 02AG/A1 CRF 02AG

13

1286

Recombinant G/A1 G

14

2492

CRF 02AG CRF 02AG

15

1037

HIV A A6

16

1048

CRF 02AG CRF 02AG

17

2356

CRF 02AG CRF 02AG

18

1170

Recombinant G/A1 Recombinant G/A1

19

1156

CRF 02AG CRF 02AG

20

1260

CRF 02AG CRF 02AG

21

2709

Recombinant 02AG/A1 CRF 02AG

22

1036

Recombinant 02AG/A1 CRF 02AG

23

2886

CRF 02AG CRF 02AG

24

2595

CRF 02AG CRF 02AG

25

2141

CRF 02AG CRF 02AG

26

2046

CRF 02AG CRF 02AG

27

1969

A A1

28

1976

A A3

29

2073

G-like G

30

2813

CRF 02AG CRF 02AG

31

2205

CRF 02AG CRF 02AG

32

2501

CRF 06CPX CRF 06CPX

33

2731

CRF 06CPX CRF 06CPX

34

2279

CRF 06CPX CRF 06CPX

35

2488

CRF 02AG CRF 02AG

36

2130

A1 A3

37

2504

CRF 02AG CRF 02AG

38

2505

CRF 02AG CRF 02AG

39

2506

CRF 02AG CRF 02AG

40

2526

CRF 02AG CRF 02AG

41

2530

A A1

42

2547

A A3

43

2562

CRF 02AG CRF 02AG

44

2564

Recombinant 02AG/A1 CRF 02AG

45

1261

A1 A3

46

2664

Recombinant 02AG/A1 CRF 02AG

47

1215

A1 A3

48

1333

Recombinant 14BG/G G

49

3816

A A3

50

2670

G G

51

2412

CRF 02AG CRF 02AG

52

2578

CRF 02AG CRF 02AG

53

6778

A A3

54

1762

CRF 02AG CRF 02AG

55

7032

CRF 02AG CRF 02AG

56

1805

CRF 02AG CRF 02AG

57

2309

CRF 02AG CRF 02AG

58

954

A A1

ref1_A3

AB098332

A3 A3

ref2_CRF02_AG

AB231896

CRF 02AG CRF 02AG

ref3__CRF02_AG

AB231898

CRF 02AG CRF 02AG

ref4_A1

AB287376

A1 A1

ref5_G

AF061641

G G

ref6_CRF02_AG

AF063224

CRF 02AG CRF 02AG

ref7_C

AF067155

C C

ref8_A1

AF069670

A1 A1

ref9_F1

AF075703

F1 F1

ref10_G

AF084936

G G

ref11_A

AF107771

A A

ref12_CRF03_AB

AF193276

CRF 03AB CRF 03AB

ref13_A2

AF286237

A2 A2

ref14_CRF02_AG

AF377954

CRF 02AG CRF 02AG

ref15_A6

AF413987

A6 A1

ref16_A1

AF484509

A1 A1

ref17_CRF02_AG

AY151001

CRF 02AG CRF 02AG

ref18_B

AY173951

B B

ref19_A6

AY500393

A6 A6

ref20_A3

AY521629

A3 A3

ref21_A3

AY521631

A3 A3

ref22_B

AY713409

B B

ref23_C

AY772699

C C

ref24_A6

EF589043

A6 A6

ref25_A1

EU110087

A1 A1

ref26_CRF02_AG

EU786671

CRF 02AG CRF 02AG

ref27_A1

EU861977

A1 A1

ref28__CRF02_AG

GU201514

CRF 02AG CRF 02AG

ref29_B

HM586190

B B

ref30_A6

HQ161930

A6 A6

ref31_A6

HQ449397

A6 A6

ref32_B

KJ771697

B B

ref33_CRF02_AG

KT124792

CRF 02AG CRF 02AG

ref34_B

M17449

B B

ref35_C

U46016

C C

ref36_A1

U51190

A1 A1

ref37_C

U52953

C C

ref38_G

U88826

G G

ref39_CRF_06cpx

MH605500.1

CRF 06cpx CRF 06cpx

ref40_CRF_06cpx

HQ529257.1

CRF 06cpx CRF 06cpx

 

References

 

1. UNAIDS data 2020. UNAIDS. Jul 2020 https://www.unaids.org/en/resources/documents/2020/unaids-data

2. UNAIDS data 2020. UNAIDS. Jul 2020

https://www.unaids.org/en/resources/documents/2020/unaids-data

3. Bekolo CE, Soumah MM, Tiemtore OW, et al. Assessing the outcomes of HIV-infected persons receiving treatment for Kaposi sarcoma in Conakry-Guinea. BMC Cancer. 2017;17(1):806. Published 2017 Dec 2. doi:10.1186/s12885-017-3771-x

4. Bbosa N, Kaleebu P, Ssemwanga D. HIV subtype diversity worldwide. Curr Opin HIV AIDS. 2019;14(3):153-160. DOI:10.1097/COH.0000000000000534

5.  Lihana RW, Ssemwanga D, Abimiku A, Ndembi N. Update on HIV-1 diversity in Africa: a decade in review. AIDS Rev 2012; 14:83–100.

6.  Nii-Trebi, Nicholas & Brandful, James & Ibe, Shiro & Sugiura, Wataru & Barnor, Jacob & Bampoh, Patrick & Yamaoka, Shoji & Matano, Tetsuro & Yoshimura, Kazuhisa & Ishikawa, Koichi & Ampofo, William. (2017). Dynamic HIV-1 genetic recombination and genotypic drug resistance among treatment-experienced adults in northern Ghana. Journal of Medical Microbiology. 66. DOI: 10.1099/jmm.0.000621.

7. Mbange AE, Kaba D, Diouara AAM, Diop-Ndiaye H, Ngom-Ngueye NF, Dieng A, Lo S, Toure KN, Fall M, Mbacham WF, Diallo MS, Cisse M, Mboup S, Kane CT. Surveillance of transmitted HIV-1 antiretroviral drug resistance in the context of decentralized HIV care in Senegal and the Ebola outbreak in Guinea. BMC Res Notes. 2018 Oct 12;11(1):723. doi: 10.1186/s13104-018-3804-9. PMID: 30309385; PMCID: PMC6182815.

8. Kumar S., Stecher G., Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis version 7.0 for bigger datasets. Mol. Biol. Evol. 2016; 33(7): 1870–4. DOI: 10.1093/molbev/msw054.

9. Svarovskaia, Evguenia & Feng, Joy & Margot, Nicolas & Myrick, Florence & Goodman, Derrick & ly, John & White, Kirsten & Kutty, Nilima & Wang, Ruth & Borroto-Esoda, Katyna & Miller, Michael. (2008). The A62V and S68G Mutations in HIV-1 Reverse Transcriptase Partially Restore the Replication Defect Associated With the K65R Mutation. Journal of acquired immune deficiency syndromes (1999). 48. 428-36. DOI:10.1097/QAI.0b013e31817bbe93.

10. Yendewa G.A., Sahr F., Lakoh S., Ruiz M., Patiño L., Tabernilla A., Deen G.F., Sesay M., Salata R.A., Poveda E. Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone. J. Antimicrob. Chemother. 2019; 74(7):2024–9. DOI: 10.1093/jac/dkz134.

11. Vingerhoets J., Peeters M., Azijn H., Tambuyzer L., Hoogstoel A., Nijs S., de Bethune M-P., Picchio G. An update of the list of NNRTI mutations associated with decreased virological response to etravirine: multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data [abstract 24]. Antiviral Therapy. 2008; 13 Suppl 3:A26.

12. Flor-Parra F, Pérez-Pulido AJ, Pachón J, Pérez-Romero P. The HIV type 1 protease L10I minor mutation decreases replication capacity and confers resistance to protease inhibitors. AIDS Res Hum Retroviruses. 2011;27(1):65-70. DOI:10.1089/aid.2010.0072

13. Vingerhoets J., Peeters M., Azijn H., Tambuyzer L., Hoogstoel A., Nijs S., de Bethune M-P., Picchio G. An update of the list of NNRTI mutations associated with decreased virological response to etravirine: multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data [abstract 24]. Antiviral Therapy. 2008; 13 Suppl 3:A26.

14.  John P. Barnard, Kelly D. Huber, Nicolas Sluis-Cremer. Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase. Antimicrobial Agents and Chemotherapy Jul 2019, 63 (8); DOI:10.1128/AAC.00676-19

15. Tambuyzer, L., H. Azijn, L. T. Rimsky, J. Vingerhoets, P. Lecocq, G. Kraus, G. Picchio, and M. P. de Bethune. 2009. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors. Antivir. Ther.14:103-109